Major Key player Arvinas announced completed Phase I and interim Phase II ARDENT data for ARV-110 degrader targeting the androgen receptor (AR). According to the results, Arvinas mentioned that at the data cut-off date, December 20, 2021, the PSA50 response rate was 46% in 28 patients with AR T878X/H875Y tumor mutations and the PSA decline of more than 30% (PSA30) response rate was 57%. In addition to that, ARV-110 had a manageable tolerability profile at the recommended Phase II dose (RP2D) of 420 mg oral, once daily. These data continue to provide evidence of anti-tumor activity and clinical benefit in patients with mCRPC. Arvinas plans to begin discussions with the...
